Evan Lytle 1 , Chad Claus 1 , Elise Yoon 1 , Doris Tong 1 , Teck Soo 1 Show Affiliations »
Abstract
BACKGROUND: The United States is facing an opioid addiction epidemic with >63,600 deaths from drug overdoses in 2016 alone. Ketorolac is a nonsteroidal anti-inflammatory drug that has been shown to decrease postoperative pain in decompressive lumbar laminectomies. We sought to demonstrate that intraoperative intramuscular (IM) ketorolac is associated with decreased opioid use in the management of acute postoperative pain in thoracolumbar spinal fusions. METHODS: A retrospective review of consecutive patients undergoing open and minimally invasive (MIS) thoracolumbar fusions between 2017 and 2018. Ketorolac (30 mg) was injected into the paraspinal muscles adjacent to the operative site before closure. Patients were placed on a standard pain control regimen. All demographic and surgical data were assessed with univariate analysis to assess for differences between groups. Univariate analysis was used to identify significant covariates for the linear regressions with postoperative morphine equivalents, length of stay (LOS), and visual analog scale (VAS) for pain as dependent variables. A P < .025 was considered significant to account for multiple covariates. RESULTS: Two hundred twenty-five consecutive patients were included with 58 patients receiving intraoperative IM ketorolac. The average age of the ketorolac groups was 63.4 years (23-87 years) with an even distribution between genders. There was no significant difference in demographic or surgical data between the 2 cohorts. Postoperative opioid use, when corrected for LOS, showed no significance between cohorts, ketorolac 16.4 mg (95% confidence interval [CI]: 12.3-20.5) and nonketorolac 6.7 mg (95% CI: 14.1-19.4, P = .8729). Other than postoperative day zero VAS (P = .05), ketorolac was not a predictor of opioid use, LOS, or VAS. CONCLUSION: The use of a single dose of intraoperative IM ketorolac did not decrease the overall opioid requirements or shorten the LOS following open or MIS lumbar fusions. However, we did demonstrate benefit in early pain control, which makes this promising for further investigation. LEVEL OF EVIDENCE: 3. CLINICAL RELEVANCE: This article promotes attention to the opioid crisis and the need for multimodal nonopioid based pain management in spine surgery. ©International Society for the Advancement of Spine Surgery 2020.
BACKGROUND: The United States is facing an opioid addiction epidemic with >63,600 deaths from drug overdoses in 2016 alone. Ketorolac is a nonsteroidal anti-inflammatory drug that has been shown to decrease postoperative pain in decompressive lumbar laminectomies. We sought to demonstrate that intraoperative intramuscular (IM) ketorolac is associated with decreased opioid use in the management of acute postoperative pain in thoracolumbar spinal fusions. METHODS: A retrospective review of consecutive patients undergoing open and minimally invasive (MIS) thoracolumbar fusions between 2017 and 2018. Ketorolac (30 mg) was injected into the paraspinal muscles adjacent to the operative site before closure. Patients were placed on a standard pain control regimen. All demographic and surgical data were assessed with univariate analysis to assess for differences between groups. Univariate analysis was used to identify significant covariates for the linear regressions with postoperative morphine equivalents, length of stay (LOS), and visual analog scale (VAS) for pain as dependent variables. A P < .025 was considered significant to account for multiple covariates. RESULTS: Two hundred twenty-five consecutive patients were included with 58 patients receiving intraoperative IM ketorolac. The average age of the ketorolac groups was 63.4 years (23-87 years) with an even distribution between genders. There was no significant difference in demographic or surgical data between the 2 cohorts. Postoperative opioid use, when corrected for LOS, showed no significance between cohorts, ketorolac 16.4 mg (95% confidence interval [CI]: 12.3-20.5) and nonketorolac 6.7 mg (95% CI: 14.1-19.4, P = .8729). Other than postoperative day zero VAS (P = .05), ketorolac was not a predictor of opioid use, LOS, or VAS. CONCLUSION: The use of a single dose of intraoperative IM ketorolac did not decrease the overall opioid requirements or shorten the LOS following open or MIS lumbar fusions. However, we did demonstrate benefit in early pain control, which makes this promising for further investigation. LEVEL OF EVIDENCE: 3. CLINICAL RELEVANCE: This article promotes attention to the opioid crisis and the need for multimodal nonopioid based pain management in spine surgery. ©International Society for the Advancement of Spine Surgery 2020.
Entities: Chemical
Keywords:
ketorolac; lumbar fusion; postoperative pain control
Year: 2020
PMID： 32699750 PMCID： PMC7343257 DOI： 10.14444/7039
Source DB: PubMed Journal: Int J Spine Surg ISSN： 2211-4599